The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by ...

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer. Among patients with heavily pretreated patients with KRAS ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

Colorectal surgeon Dr. Julio Garcia-Aguilar says there are a growing number of ways to treat colon and rectal cancer including advances in targeted therapy, surgery, and immunotherapy that can also ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...

Research shows that gastrointestinal cancers — including stomach, liver, esophageal, pancreatic, and colorectal cancers — account for about 26% of all cancers worldwide and 35% of all cancer-related ...